Moving beyond the conventional stratified analysis to estimate an overall treatment efficacy with the data from a comparative randomized clinical study

For a two‐group comparative study, a stratified inference procedure is routinely used to estimate an overall group contrast to increase the precision of the simple two‐sample estimator. Unfortunately, most commonly used methods including the Cochran‐Mantel‐Haenszel statistic for a binary outcome and the stratified Cox procedure for the event time endpoint do not serve this purpose well. In fact, these procedures may be worse than their two‐sample counterparts even when the observed treatment allocations are imbalanced across strata. Various procedures beyond the conventional stratified methods have been proposed to increase the precision of estimation when the naive estimator is consistent. In this paper, we are interested in the case when the treatment allocation proportions vary markedly across strata. We study the stochastic properties of the two‐sample naive estimator conditional on the ancillary statistics, the observed treatment allocation proportions and/or the stratum sizes, and present a biased‐adjusted estimator. This adjusted estimator is asymptotically equivalent to the augmentation estimators proposed under the unconditional setting. Moreover, this consistent estimation procedure is also equivalent to a rather simple procedure, which estimates the mean response of each treatment group first via a stratum‐size weighted average and then constructs the group contrast estimate. This simple procedure is flexible and readily applicable to any target patient population by choosing appropriate stratum weights. All the proposals are illustrated with the data from a cardiovascular clinical trial, whose treatment allocations are imbalanced.

[1]  H. Uno,et al.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. , 2015, Annals of internal medicine.

[2]  Cun-Hui Zhang,et al.  Lasso adjustments of treatment effect estimates in randomized experiments , 2015, Proceedings of the National Academy of Sciences.

[3]  Yoshiaki Uyama,et al.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Luke W. Miratrix,et al.  Adjusting treatment effect estimates by post‐stratification in randomized experiments , 2013 .

[5]  D. Mehrotra,et al.  An efficient alternative to the stratified Cox model analysis , 2012, Statistics in medicine.

[6]  Lihui Zhao,et al.  On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trial. , 2012, Biostatistics.

[7]  Michael Rosenblum,et al.  Targeted Maximum Likelihood Estimation of the Parameter of a Marginal Structural Model , 2010, The international journal of biostatistics.

[8]  M J van der Laan,et al.  Covariate adjustment in randomized trials with binary outcomes: Targeted maximum likelihood estimation , 2009, Statistics in medicine.

[9]  M. Davidian,et al.  Covariate adjustment for two‐sample treatment comparisons in randomized clinical trials: A principled yet flexible approach , 2008, Statistics in medicine.

[10]  Marie Davidian,et al.  Improving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates , 2008, Biometrics.

[11]  D. Fraser Ancillaries and Conditional Inference , 2004 .

[12]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[13]  S. Pocock,et al.  Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.

[14]  Ji Zhang,et al.  Analysis of Data with Imbalance in the Baseline Outcome Variable for Randomized Clinical Trials , 2001 .

[15]  G G Koch,et al.  Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. , 1998, Statistics in medicine.

[16]  Richard Valliant,et al.  Poststratification and Conditional Variance Estimation , 1993 .

[17]  S J Senn,et al.  Covariate imbalance and random allocation in clinical trials. , 1989, Statistics in medicine.

[18]  John D. Kalbfleisch,et al.  Sufficiency and conditionality , 1975 .

[19]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[20]  D.,et al.  Regression Models and Life-Tables , 2022 .